Augmented renal clearance in critically ill patients: Etiology, definition and implications for beta-lactam dose optimization

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 1-6

  Sime, Fekade Bruck ^a   Udy, Andrew A ^a,b,c   Roberts, Jason A ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CREATININE; PIPERACILLIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; AUGMENTED RENAL CLEARANCE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DOSE OPTIMIZATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MONITORING; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; KIDNEY CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; CRITICAL ILLNESS; DOSE RESPONSE; KIDNEY; METABOLISM;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY;

EID: 84934978398     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.06.002     Document Type: Review

References (37)

1. A.A. Udy, P. Jarrett, J. Stuart, M. Lassig-Smith, T. Starr, R. Dunlop, S.C. Wallis, and J.A.J.L. Roberts Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds Crit Care 18 2014 657
2. A.A. Udy, J.P. Baptista, N.L. Lim, G.M. Joynt, P. Jarrett, L. Wockner, R.J. Boots, and J. Lipman Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations Crit Care Med 42 2014 520 527
3. J.P. Baptista, M. Neves, L. Rodrigues, L. Teixeira, J. Pinho, and J. Pimentel Accuracy of the estimation of glomerular filtration rate within a population of critically ill patients J Nephrol 27 2014 403 410
4. B.O. Claus, E.A. Hoste, K. Colpaert, H. Robays, J. Decruyenaere, and J.J. De Waele Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy J Crit Care 28 2013 695 700
5. A.A. Udy, J.A. Roberts, A.F. Shorr, R.J. Boots, and J. Lipman Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients Crit Care 17 2013 R35
6. C.C. May, S. Arora, S.E. Parli, J.F. Fraser, M.T. Bastin, and A.M. Cook Augmented renal clearance in patients with subarachnoid hemorrhage Neurocrit Care 2015 http://dx.doi.org/10.1007/s12028-015-0127-8 [Epub ahead of print]
7. S. Adnan, S. Ratnam, S. Kumar, D. Paterson, J. Lipman, J. Roberts, and A.A. Udy Select critically ill patients at risk of augmented renal clearance: experience in a Malaysian intensive care unit Anaesth Intens Care 42 2014 715 722
8. J.J. De Waele, A. Dumoulin, A. Janssen, and E.A. Hoste Epidemiology of augmented renal clearance in mixed ICU patients Minerva Anestesiol 2015 [Epub ahead of print]
9. A.A. Udy, J.M. Varghese, M. Altukroni, S. Briscoe, B.C. McWhinney, J.P. Ungerer, J. Lipman, and J.A. Roberts Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations Chest 142 2012 30 39
10. A. Huttner, E. Von Dach, A. Renzoni, B.D. Huttner, M. Affaticati, L. Pagani, Y. Daali, J. Pugin, A. Karmime, M. Fathi, and et al. Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study Int J Antimicrob Agents 45 2015 385 392
11. M.L. Campassi, M.C. Gonzalez, F.D. Masevicius, A.R. Vazquez, M. Moseinco, N.C. Navarro, L. Previgliano, N.P. Rubatto, M.H. Benites, E. Estenssoro, and et al. Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment Rev Brasil Terapia Intensiva 26 2014 13 20
12. A.A. Udy, J.A. Roberts, R.J. Boots, D.L. Paterson, and J. Lipman Augmented renal clearance: implications for antibacterial dosing in the critically ill Clin Pharmacokinet 49 2010 1 16
13. A.A. Udy, J. Lipman, P. Jarrett, K. Klein, S.C. Wallis, K. Patel, C.M.J. Kirkpatrick, P.S. Kruger, D.L. Paterson, M.S. Roberts, and et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 19 2015 28
14. Y. Shimamoto, T. Fukuda, K. Tanaka, K. Komori, and D. Sadamitsu Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis Intensive Care Med 39 2013 1247 1252
15. S.I. Blot, F. Pea, and J. Lipman The effect of pathophysiology on pharmacokinetics in the critically ill patient - concepts appraised by the example of antimicrobial agents Adv Drug Del Rev 77 2014 3 11
16. R. Minkute, V. Briedis, R. Steponaviciute, A. Vitkauskiene, and R. Maciulaitis Augmented renal clearance - an evolving risk factor to consider during the treatment with vancomycin J Clin Pharm Ther 38 2013 462 467
17. K.S. Akers, K.L. Niece, K.K. Chung, J.W. Cannon, J.M. Cota, and C.K. Murray Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients J Trauma Acute Care Surg 77 2014 S163 S170
18. A.A. Udy, F.J. Morton, S. Nguyen-Pham, P. Jarrett, M. Lassig-Smith, J. Stuart, R. Dunlop, T. Starr, R.J. Boots, and J. Lipman A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations BMC Nephrol 14 2013 250
19. J.P. Baptista, A.A. Udy, E. Sousa, J. Pimentel, L. Wang, J.A. Roberts, and J. Lipman A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance Crit Care 15 2011 R139
20. V. Grootaert, L. Willems, Y. Debaveye, G. Meyfroidt, and I. Spriet Augmented renal clearance in the critically ill: how to assess kidney function Ann Pharmacother 46 2012 952 959
21. J.H. Martin, M.F. Fay, A. Udy, J. Roberts, C. Kirkpatrick, J. Ungerer, and J. Lipman Pitfalls of using estimations of glomerular filtration rate in an intensive care population Intern Med J 41 2011 537 543
22. G. Bragadottir, B. Redfors, and S.E. Ricksten Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury - true GFR versus urinary creatinine clearance and estimating equations Crit Care 17 2013 R108
23. M. Carlier, A. Dumoulin, A. Janssen, S. Picavet, S. Vanthuyne, R. Van Eynde, R. Vanholder, J. Delanghe, G. De Schoenmakere, J.J. De Waele, and et al. Comparison of different equations to assess glomerular filtration in critically ill patients Intens Care Med 41 2015 427 435
24. J.J. Dixon, K. Lane, R.N. Dalton, C. Turner, R.M. Grounds, I.A. MacPhee, and B.J. Philips Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial J Transl Med 13 2015 58
25. S.H. Kwon, A. Saad, S.M. Herrmann, S.C. Textor, and L.O. Lerman Determination of single-kidney glomerular filtration rate in human subjects by using CT Radiology 2015 141892
26. F.B. Sime, M.S. Roberts, S.L. Peake, J. Lipman, and J.A. Roberts Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review Ann Intens Care 2 2012 35
27. J.A. Roberts, S.K. Paul, M. Akova, M. Bassetti, J.J. De Waele, G. Dimopoulos, K.M. Kaukonen, D. Koulenti, C. Martin, P. Montravers, and et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 2014 1072 1083
28. M. Carlier, S. Carrette, J.A. Roberts, V. Stove, A. Verstraete, E. Hoste, P. Depuydt, J. Decruyenaere, J. Lipman, S.C. Wallis, and et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 17 2013 R84
29. J.A. Roberts, and J. Lipman Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility Crit Care Med 41 2013 489 495
30. A.M. Cook, S. Arora, J. Davis, and T. Pittman Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient Neurocrit Care 19 2013 210 214
31. M. Carlier, S. Carrette, V. Stove, A.G. Verstraete, and J.J. De Waele Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course Int J Antimicrob Agents 43 2014 470 473
32. J.M. Dulhunty, J.A. Roberts, J.S. Davis, S.A. Webb, R. Bellomo, C. Gomersall, C. Shirwadkar, G.M. Eastwood, J. Myburgh, D.L. Paterson, and et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial Clin Infect Dis 56 2013 236 244
33. J.A. Roberts, M.H. Abdul-Aziz, J. Lipman, J.W. Mouton, A.A. Vinks, T.W. Felton, W.W. Hope, A. Farkas, M.N. Neely, J.J. Schentag, and et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions Lancet Infect Dis 14 2014 498 509
34. G. Wong, A. Brinkman, R.J. Benefield, M. Carlier, J.J. De Waele, N. El Helali, O. Frey, S. Harbarth, A. Huttner, B. McWhinney, and et al. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units J Antimicrob Chemother 69 2014 1416 1423
35. J.J. De Waele, S. Carrette, M. Carlier, V. Stove, J. Boelens, G. Claeys, I. Leroux-Roels, E. Hoste, P. Depuydt, J. Decruyenaere, and et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial Intens Care Med 40 2014 380 387
36. F.B. Sime, M.S. Roberts, I.S. Tiong, J.H. Gardner, S. Lehman, S.L. Peake, U. Hahn, M.S. Warner, and J.A. Roberts Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial J Antimicrob Chemother 2015 http://dx.doi.org/10.1093/jac/dkv123. [Epub ahead of print]
37. T.W. Felton, J.A. Roberts, T.P. Lodise, M. Van Guilder, E. Boselli, M.N. Neely, and W.W. Hope Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy Antimicrob Agents Chemother 58 2014 4094 4102.